Judith Wasserheit, MD, MPH, BA
Chair, Global Health
Professor, Allergy and Infectious Dis.
Professor, Global Health
Adjunct Professor, Epidemiology
Judith N. Wasserheit is a Professor of Medicine and Global Health and William H. Foege Endowed Chair of the Department of Global Health. She is also an Affiliate Investigator the Fred Hutchinson Cancer Research Center. She was formerly the Director of the HIV Vaccine Trials Network, a global clinical trials platform linking 28 sites on four continents in evaluating preventive HIV vaccines; led the CDC's national STD prevention program for almost a decade; and was the founding chief of the NIH's STD research branch. She has had extensive experience in sexually transmitted disease (STD) and HIV research, policy development, and program implementation both in the United States and in developing countries.
Current research interests include: examining the effects of co-infection such as sexually transmitted infections, malaria, TB, and HCV on HIV acquisition and transmission; designing and evaluating combination HIV prevention packages for sub-Saharan Africa; developing and evaluating multi-component interventions to reduce STDs, HIV, and pregnancy among women and adolescents, and developing and evaluating approaches to adaptation to climate change to reduce the impact on human health.
University of Washington
Harris Hydraulics Building
1705 NE Pacific St.
Seattle, WA 98195
Impact of HIV and other STDs on women and adolescents; STD/HIV interactions; HIV vaccine clinical trials; implementation science and program management
MPH, Public Health, Johns Hopkins University 1989
MD, Medicine, Harvard University 1978
BA, Biochemistry, Slavic Lang & Lit, Princeton University 1974
Sherr, KS, Gimbel S, Rustagi A, Nduati R, Cuembelo F, Farquhar C, Wasserheit JN, Gloyd SG, With input from the SAIA Study Team. Systems analysis and improvement to optimize pMTCT (SAIA): a cluster randomized trial. Implementation Science 2014. May 8;9:55. DOI 10.1186/1748-5908-9-55.
Abu-Raddad LJ, Barnabas RV, Janes H, Kublin J, Longini IG, Weiss H, Wasserheit JN and the HIV Viral Load Working Group. Have the explosive HIV epidemics in sub-Saharan Africa been driven by higher community viral load? AIDS 2013, 27:981-989
Kirkcaldy RD, Bolan GA, Wasserheit JN. Cephalosporin-resistant gonorrhea in North America. JAMA 2013;309(2):185-7
Pfeiffer J, Beschta J, Hohl S, Gloyd S, Hagopian A, Wasserheit JN. Competency-based curricula to transform global health: Redesign with the end in mind. Academic Medicine 2013;88:131-136.
Hartwell TD, Pequenat W, Moore J, Parker CB, Strader LC, Green AM, Quinn TC, Wasserheit JN, Klausner, JD, NIMH Collaborative HIV/STD Prevention Trial Group. The Utility of a Composite Biological Endpoint in HIV/STD Prevention Trials. AIDS and Behavior 2013. DOI 10.1007/s10461-013-0501-5.
Bolan GA, Sparling PF, Wasserheit JN. The emerging threat of untreatable gonococcal infection. N Engl J Med. 2012 Feb 9;366(6):485-7. PMID:22316442.
Moreno MA, Brockman LN, Wasserheit JN, Christakis DA. A pilot evaluation of older adolescents' sexual reference displays on Facebook. J Sex Res. 2012;49(4):390-9. Epub 2012 Jan 12. PMID:22239559.
Barnabas RV, Wasserheit JN, Huang Y, Janes H, Morrow R, Fuchs J, Mark KE, Casapia M, Mehrotra DV, Buchbinder SP, Corey L; NIAID HIV Vaccine Trials Network. Impact of herpes simplex virus type 2 on HIV-1 acquisition and progression in an HIV vaccine trial (the Step study). J Acquir Immune Defic Syndr. 2011 Jul 1;57(3):238-44. PMID:21860356.
SciVal Experts Page